{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Alolayan S"],"pubmed_abstract":["<b>Introduction:</b> Based on previously published US Diabetes Prevention Program (DPP) cost-effectiveness analyses (CEAs), metformin continues to be promoted as \"cost-effective.\" We reviewed a 10-year CEA to assess this. Treatment alternatives included placebo, branded metformin and individual lifestyle modification. Following the original CEA, we added group lifestyle as a modeled alternative. <b>Methods:</b> Original published data were taken as given and re-analyzed according to accepted principles for calculating incremental cost-effectiveness ratios (ICERs). With more than 2 treatments, these require attention to the rankings of interventions according to cost or effect prior to stipulating appropriate ICERs to calculate. <b>Results:</b> With appropriate ICER calculations, metformin "],"journal":["American journal of lifestyle medicine"],"pagination":["15598276251315415"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11752154"],"repository":["biostudies-literature"],"pubmed_title":["Incremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes Study."],"pmcid":["PMC11752154"],"pubmed_authors":["Doucette J","Rittenhouse BE","Segal AR","Alolayan S","Eguale T"],"additional_accession":[]},"is_claimable":false,"name":"Incremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes Study.","description":"<b>Introduction:</b> Based on previously published US Diabetes Prevention Program (DPP) cost-effectiveness analyses (CEAs), metformin continues to be promoted as \"cost-effective.\" We reviewed a 10-year CEA to assess this. Treatment alternatives included placebo, branded metformin and individual lifestyle modification. Following the original CEA, we added group lifestyle as a modeled alternative. <b>Methods:</b> Original published data were taken as given and re-analyzed according to accepted principles for calculating incremental cost-effectiveness ratios (ICERs). With more than 2 treatments, these require attention to the rankings of interventions according to cost or effect prior to stipulating appropriate ICERs to calculate. <b>Results:</b> With appropriate ICER calculations, metformin ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2025-04-05T00:25:30.823Z","creation":"2025-04-05T00:25:30.823Z"},"accession":"S-EPMC11752154","cross_references":{"pubmed":["39850322"],"doi":["10.1177/15598276251315415"]}}